Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy

Inclusion Criteria:

1. Age ≥ 70 years;

2. ECOG score 0-3;

3. Rated as "unfit" or "frail" on the simplified geriatric assessment (sGA);

4. Histologically confirmed CD20-positive diffuse large B-cell lymphoma [diagnosticcriteria according to WHO 2016], excluding transformed type 2 DLBCL;

5. Previously untreated, newly diagnosed patients;

6. Cardiac, hepatic, and renal function: creatinine < 2 times the upper limit of normal (ULN); ALT (alanine aminotransferase) / AST (aspartate aminotransferase) < 2.5 xULN; total bilirubin < 2 x ULN;

7. At least one measurable lesion;

8. Intolerance to standard CHOP chemotherapy regimen or unwillingness to receivechemotherapy;

9. Sufficient understanding and voluntary signing of the informed consent form.

Exclusion Criteria:

1. Patients with central nervous system involvement at the onset of the disease;

2. Known human immunodeficiency virus (HIV) infection;

3. Pregnant or lactating women;

4. Other tumors requiring treatment;

5. Uncontrolled active infection;

6. Active hepatitis with HBV-DNA copy number unable to be controlled within 2000/mLdespite antiviral treatment;

7. Individuals who cannot understand, comply with the study protocol, or sign theinformed consent form.